CytRx Stock Price, News & Analysis (NASDAQ:CYTR)

$1.76 -0.04 (-2.22 %)
(As of 01/22/2018 08:09 AM ET)
Previous Close$1.80
Today's Range$1.75 - $1.80
52-Week Range$1.65 - $6.00
Volume347,000 shs
Average Volume217,608 shs
Market Capitalization$48.64 million
P/E Ratio-1.01
Dividend YieldN/A
Beta2.27

About CytRx (NASDAQ:CYTR)

CytRx logoCytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed after treatment with chemotherapy. It is also involved in evaluating aldoxorubicin in a Phase IIb clinical trial in small cell lung cancer; a Phase II clinical trial in human immunodeficiency virus-related Kaposi's sarcoma; a Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); a Phase Ib trial in combination with ifosfamide in patients with STS, and a Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. It is engaged in the pre-clinical development for DK049, an anti-cancer drug conjugate that utilizes its Linker Activated Drug Release (LADR) technology.

Receive CYTR News and Ratings via Email

Sign-up to receive the latest news and ratings for CYTR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CYTR
CUSIPN/A
Phone310-826-5648

Debt

Debt-to-Equity RatioN/A
Current Ratio1.71%
Quick Ratio1.71%

Price-To-Earnings

Trailing P/E Ratio-1.0058867234383
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$200,000.00
Price / Sales243.23
Cash FlowN/A
Price / CashN/A
Book Value$1.20 per share
Price / Book1.47

Profitability

Trailing EPS($1.75)
Net Income$-50,760,000.00
Net MarginsN/A
Return on Equity-210.45%
Return on Assets-72.41%

Miscellaneous

Employees27
Outstanding Shares27,640,000

CytRx (NASDAQ:CYTR) Frequently Asked Questions

What is CytRx's stock symbol?

CytRx trades on the NASDAQ under the ticker symbol "CYTR."

When did CytRx's stock split? How did CytRx's stock split work?

CytRx's stock reverse split on the morning of Wednesday, November 1st 2017. The 1-6 reverse split was announced on Friday, October 27th 2017. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, October 31st 2017. An investor that had 100 shares of CytRx stock prior to the reverse split would have 17 shares after the split.

How were CytRx's earnings last quarter?

CytRx Co. (NASDAQ:CYTR) issued its quarterly earnings data on Wednesday, November, 8th. The biotechnology company reported ($0.33) EPS for the quarter. View CytRx's Earnings History.

When will CytRx make its next earnings announcement?

CytRx is scheduled to release their next quarterly earnings announcement on Tuesday, March, 13th 2018. View Earnings Estimates for CytRx.

Where is CytRx's stock going? Where will CytRx's stock price be in 2018?

2 Wall Street analysts have issued 12-month target prices for CytRx's shares. Their predictions range from $24.00 to $24.00. On average, they expect CytRx's stock price to reach $24.00 in the next twelve months. View Analyst Ratings for CytRx.

Who are some of CytRx's key competitors?

Who are CytRx's key executives?

CytRx's management team includes the folowing people:

  • John Y Caloz, Chief Financial Officer (Age 63)
  • David J. Haen, Vice President - Business Development (Age 37)
  • Olivia C. Ware, Chief Commercial Officer
  • Steven A. Kriegsman, Chairman of the Board, President, Chief Executive Officer (Age 73)
  • Earl W. Brien M.D., Director (Age 56)
  • Joel Caldwell, Director (Age 62)
  • Louis J. Ignarro Ph.D., Independent Director (Age 73)

How do I buy CytRx stock?

Shares of CytRx can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CytRx's stock price today?

One share of CytRx stock can currently be purchased for approximately $1.76.

How big of a company is CytRx?

CytRx has a market capitalization of $48.64 million and generates $200,000.00 in revenue each year. The biotechnology company earns $-50,760,000.00 in net income (profit) each year or ($1.75) on an earnings per share basis. CytRx employs 27 workers across the globe.

How can I contact CytRx?

CytRx's mailing address is 11726 SAN VICENTE BOULEVARD SUITE 650, LOS ANGELES CA, 90049. The biotechnology company can be reached via phone at 310-826-5648 or via email at [email protected]


MarketBeat Community Rating for CytRx (CYTR)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  213 (Vote Outperform)
Underperform Votes:  130 (Vote Underperform)
Total Votes:  343
MarketBeat's community ratings are surveys of what our community members think about CytRx and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

CytRx (NASDAQ:CYTR) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $24.00$24.00$21.00$21.00
Price Target Upside: 396.46% upside396.46% upside334.40% upside334.40% upside

CytRx (NASDAQ:CYTR) Consensus Price Target History

Price Target History for CytRx (NASDAQ:CYTR)

CytRx (NASDAQ:CYTR) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/26/2017HC WainwrightReiterated RatingBuy$24.00HighView Rating Details
3/21/2017AegisReiterated RatingBuyMediumView Rating Details
11/14/2016FBR & CoSet Price TargetBuy$18.00N/AView Rating Details
7/15/2016Jefferies GroupReiterated RatingHold$15.00 -> $4.50N/AView Rating Details
7/12/2016S&P Equity ResearchLower Price Target$6.24 -> $4.50N/AView Rating Details
(Data available from 1/22/2016 forward)

Earnings

CytRx (NASDAQ:CYTR) Earnings History and Estimates Chart

Earnings by Quarter for CytRx (NASDAQ:CYTR)

CytRx (NASDAQ CYTR) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/13/2018N/AView Earnings Details
11/8/2017Q3 2017($0.33)ViewN/AView Earnings Details
8/3/2017Q2 2017($0.42)ViewN/AView Earnings Details
5/10/2017Q1 2017($0.60)ViewN/AView Earnings Details
3/15/2017Q4 2016($0.66)($0.60)ViewN/AView Earnings Details
11/9/2016Q3 2016($0.96)($0.78)ViewN/AView Earnings Details
7/29/2016Q2($1.14)($1.62)$0.10 millionViewN/AView Earnings Details
5/11/2016Q116($1.56)($1.14)ViewN/AView Earnings Details
3/11/2016Q4 2015($1.20)($2.10)ViewN/AView Earnings Details
11/3/2015Q315($1.44)($1.02)ViewN/AView Earnings Details
8/3/2015Q215($1.62)($1.50)ViewN/AView Earnings Details
5/1/2015Q115($1.26)($1.68)ViewN/AView Earnings Details
3/10/2015Q4 2014($1.62)($1.44)$0.10 millionViewN/AView Earnings Details
11/4/2014Q314($1.50)($0.60)ViewN/AView Earnings Details
8/6/2014Q214($1.20)($1.68)ViewN/AView Earnings Details
5/1/2014Q1 2014($1.08)ViewN/AView Earnings Details
3/5/2014($1.02)($1.50)$0.10 millionViewN/AView Earnings Details
10/29/2013Q313($1.32)($1.98)$0.20 millionViewN/AView Earnings Details
8/6/2013Q2 2013($1.14)($0.66)ViewN/AView Earnings Details
5/9/2013Q113($0.90)($1.38)ViewN/AView Earnings Details
3/11/2013Q4 2012($1.20)($1.26)ViewN/AView Earnings Details
11/9/2012Q312$0.42ViewN/AView Earnings Details
8/9/2012Q2 2012($1.86)($1.34)ViewN/AView Earnings Details
5/10/2012Q1 2012($1.68)($1.76)ViewN/AView Earnings Details
3/13/2012Q4 2011($1.68)($1.72)ViewN/AView Earnings Details
11/8/2011Q3 2011($1.68)($1.05)ViewN/AView Earnings Details
8/9/2011Q2 2011($2.10)($1.43)ViewN/AView Earnings Details
5/5/2011Q1 2011($1.26)($2.60)ViewN/AView Earnings Details
3/11/2011Q4 2010$2.27ViewN/AView Earnings Details
11/8/2010Q3 2010($2.10)($1.68)ViewN/AView Earnings Details
8/9/2010Q2 2010($2.10)($1.89)ViewN/AView Earnings Details
5/6/2010Q1 2010($1.68)($1.81)ViewN/AView Earnings Details
3/15/2010Q4 2009($1.68)($1.26)ViewN/AView Earnings Details
11/9/2009Q3 2009$0.42$1.51ViewN/AView Earnings Details
8/10/2009Q2 2009($1.68)($1.01)ViewN/AView Earnings Details
5/12/2009Q1 2009($1.68)($1.81)ViewN/AView Earnings Details
3/13/2009Q4 2008($1.68)($1.76)ViewN/AView Earnings Details
11/7/2008Q3 2008($1.68)($1.34)ViewN/AView Earnings Details
8/12/2008Q2 2008($2.52)($1.68)ViewN/AView Earnings Details
5/20/2008Q1 2008($3.36)($2.85)ViewN/AView Earnings Details
4/2/2008Q4 2007($2.94)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

CytRx (NASDAQ:CYTR) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for CytRx (NASDAQ:CYTR)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

CytRx (NASDAQ CYTR) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.30%
Institutional Ownership Percentage: 44.82%
Insider Trades by Quarter for CytRx (NASDAQ:CYTR)
Institutional Ownership by Quarter for CytRx (NASDAQ:CYTR)

CytRx (NASDAQ CYTR) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/3/2013Scott Bradford Pattersonmajor shareholderBuy284,979$2.44$695,348.764,912,584View SEC Filing  
11/7/2013Scott Bradford PattersonMajor ShareholderBuy50,000$2.06$103,000.00View SEC Filing  
4/1/2013Scott Bradford PattersonMajor ShareholderBuy4,083$2.70$11,024.10View SEC Filing  
3/20/2013Scott Bradford PattersonMajor ShareholderBuy3,980$2.61$10,387.80View SEC Filing  
3/13/2013Scott Bradford PattersonMajor ShareholderBuy55,360$2.67$147,811.20View SEC Filing  
10/22/2012Scott Bradford PattersonMajor ShareholderBuy180,000$2.51$451,800.00View SEC Filing  
10/18/2012Scott Bradford PattersonMajor ShareholderBuy1,200,000$2.50$3,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

CytRx (NASDAQ CYTR) News Headlines

Source:
DateHeadline
CytRx Corporation Highlights Dosing of the First Patient in Licensee NantCell Inc. Clinical Trial Investigating Cell-Based Therapy in Combination with Multiple Anti-Cancer Agents, Including Aldoxorubicin, in Patients with Metastatic Pancreatic CancerCytRx Corporation Highlights Dosing of the First Patient in Licensee NantCell Inc. Clinical Trial Investigating Cell-Based Therapy in Combination with Multiple Anti-Cancer Agents, Including Aldoxorubicin, in Patients with Metastatic Pancreatic Cancer
finance.yahoo.com - January 17 at 9:36 AM
CytRx Corporation to Present at Biotech Showcase 2018CytRx Corporation to Present at Biotech Showcase 2018
finance.yahoo.com - January 3 at 5:09 PM
Financial Analysis: CytRx (CYTR) vs. Its PeersFinancial Analysis: CytRx (CYTR) vs. Its Peers
www.americanbankingnews.com - December 11 at 11:26 AM
CytRx Corporation Provides Update on Presentations at Upcoming Investor ConferencesCytRx Corporation Provides Update on Presentations at Upcoming Investor Conferences
finance.yahoo.com - December 7 at 10:00 AM
Comparing CytRx (CYTR) & The CompetitionComparing CytRx (CYTR) & The Competition
www.americanbankingnews.com - December 6 at 11:20 AM
CytRx Corporation Announces Filing of Key Provisional Patent Applications for Ultra-High Potency LADR™ Drug CandidatesCytRx Corporation Announces Filing of Key Provisional Patent Applications for Ultra-High Potency LADR™ Drug Candidates
finance.yahoo.com - December 6 at 9:54 AM
ValuEngine Downgrades CytRx (CYTR) to Strong SellValuEngine Downgrades CytRx (CYTR) to Strong Sell
www.americanbankingnews.com - December 3 at 5:12 PM
Critical Comparison: CytRx (CYTR) versus Its CompetitorsCritical Comparison: CytRx (CYTR) versus Its Competitors
www.americanbankingnews.com - November 29 at 3:20 PM
CytRx Corporation to Present at Upcoming Investor ConferencesCytRx Corporation to Present at Upcoming Investor Conferences
finance.yahoo.com - November 27 at 6:06 PM
Today’s Research Reports on Stocks to Watch: Eleven Biotherapeutics and CytRx CorporationToday’s Research Reports on Stocks to Watch: Eleven Biotherapeutics and CytRx Corporation
finance.yahoo.com - November 20 at 6:43 PM
CytRx (CYTR) Regains Nasdaq Listing ComplianceCytRx (CYTR) Regains Nasdaq Listing Compliance
www.streetinsider.com - November 18 at 5:20 PM
CytRx Corporation Regains Nasdaq Listing Compliance - PR Newswire (press release)CytRx Corporation Regains Nasdaq Listing Compliance - PR Newswire (press release)
www.prnewswire.com - November 17 at 11:39 PM
Contrasting CytRx Corporation (CYTR) and Its CompetitorsContrasting CytRx Corporation (CYTR) and Its Competitors
www.americanbankingnews.com - November 17 at 9:30 PM
Analyzing CytRx Corporation (CYTR) and Its PeersAnalyzing CytRx Corporation (CYTR) and Its Peers
www.americanbankingnews.com - November 17 at 2:08 PM
CytRx Corporation Regains Nasdaq Listing ComplianceCytRx Corporation Regains Nasdaq Listing Compliance
finance.yahoo.com - November 17 at 1:35 PM
CytRx Corporation Provides Business Update and Announces New Shareholder Initiatives - PR Newswire (press release)CytRx Corporation Provides Business Update and Announces New Shareholder Initiatives - PR Newswire (press release)
www.prnewswire.com - November 15 at 4:11 AM
BRIEF-Cytrx announces new shareholder initiativesBRIEF-Cytrx announces new shareholder initiatives
www.reuters.com - November 13 at 12:26 PM
CytRx Corporation Provides Business Update and Announces New Shareholder InitiativesCytRx Corporation Provides Business Update and Announces New Shareholder Initiatives
finance.yahoo.com - November 13 at 12:26 PM
CytRx Reports Third Quarter 2017 Financial Results - PR Newswire (press release)CytRx Reports Third Quarter 2017 Financial Results - PR Newswire (press release)
www.prnewswire.com - November 9 at 5:34 AM
CytRx reports 3Q lossCytRx reports 3Q loss
finance.yahoo.com - November 9 at 12:32 AM
Is CytRx Corporation’s (CYTR) Balance Sheet A Threat To Its Future?Is CytRx Corporation’s (CYTR) Balance Sheet A Threat To Its Future?
finance.yahoo.com - November 8 at 2:07 AM
BRIEF-Cytrx reports strategic realignment of clinical development teamBRIEF-Cytrx reports strategic realignment of clinical development team
www.reuters.com - November 7 at 12:06 AM
CytRx Announces Strategic Realignment of Clinical Development ... - PR Newswire (press release)CytRx Announces Strategic Realignment of Clinical Development ... - PR Newswire (press release)
www.prnewswire.com - November 6 at 7:03 PM
CytRx Announces Strategic Realignment of Clinical Development TeamCytRx Announces Strategic Realignment of Clinical Development Team
finance.yahoo.com - November 6 at 7:03 PM
CytRx Corporation Highlights Recent Progress at Freiburg, Germany, Laboratory and Provides Update for Oncology PipelineCytRx Corporation Highlights Recent Progress at Freiburg, Germany, Laboratory and Provides Update for Oncology Pipeline
finance.yahoo.com - November 2 at 6:43 PM
CytRx (CYTR) Announces 1-for-6 Reverse Stock Split Will be Effective Nov. 1CytRx (CYTR) Announces 1-for-6 Reverse Stock Split Will be Effective Nov. 1
www.streetinsider.com - November 1 at 6:44 PM
CytRx Corporation Announces Reverse Stock Split - PR Newswire (press release)CytRx Corporation Announces Reverse Stock Split - PR Newswire (press release)
www.prnewswire.com - November 1 at 5:00 AM
BRIEF-Cytrx Corp announces reverse stock splitBRIEF-Cytrx Corp announces reverse stock split
www.reuters.com - October 31 at 6:56 PM
CytRx Corporation Announces Reverse Stock SplitCytRx Corporation Announces Reverse Stock Split
finance.yahoo.com - October 31 at 6:56 PM
CytRx Corporation (CYTR) to Release Earnings on TuesdayCytRx Corporation (CYTR) to Release Earnings on Tuesday
www.americanbankingnews.com - October 31 at 8:08 AM
CytRx (CYTR) Stockholders Approve 1-for-6 Reverse Stock Split ResolutionCytRx (CYTR) Stockholders Approve 1-for-6 Reverse Stock Split Resolution
www.streetinsider.com - October 29 at 5:07 PM
CytRx Corporation Announces Results from Special Meeting of Stockholders - PR Newswire (press release)CytRx Corporation Announces Results from Special Meeting of Stockholders - PR Newswire (press release)
www.prnewswire.com - October 28 at 5:57 AM
CytRx Corporation Announces Results from Special Meeting of StockholdersCytRx Corporation Announces Results from Special Meeting of Stockholders
finance.yahoo.com - October 28 at 12:57 AM
BRIEF-Cytrx corp says ‍Nasdaq has granted cos request for a continued listingBRIEF-Cytrx corp says ‍Nasdaq has granted co's request for a continued listing
www.reuters.com - October 17 at 4:33 AM
CytRx Corporation Announces Outcome of Nasdaq Hearing - PR Newswire (press release)CytRx Corporation Announces Outcome of Nasdaq Hearing - PR Newswire (press release)
www.prnewswire.com - October 16 at 11:29 PM
CytRx Corporation Announces Outcome of Nasdaq HearingCytRx Corporation Announces Outcome of Nasdaq Hearing
finance.yahoo.com - October 16 at 6:25 PM
BRIEF-Cytrx highlights inclusion of aldoxorubicin in pending upcoming clinical trial submissions - ReutersBRIEF-Cytrx highlights inclusion of aldoxorubicin in pending upcoming clinical trial submissions - Reuters
www.reuters.com - October 12 at 11:34 PM
BRIEF-Cytrx highlights inclusion of aldoxorubicin in pending upcoming clinical trial submissionsBRIEF-Cytrx highlights inclusion of aldoxorubicin in pending upcoming clinical trial submissions
www.reuters.com - October 12 at 6:33 PM
NantKwest, NantCell, And Dr. Soon-Shiongs 2020 Cancer VisionNantKwest, NantCell, And Dr. Soon-Shiong's 2020 Cancer Vision
seekingalpha.com - October 11 at 7:19 PM
Johnson Fistel, Announces Investigations of NantKwest, Inc., K12 Inc., and CytRx Corporation; Long-Term Investors ... - PR Newswire (press release)Johnson Fistel, Announces Investigations of NantKwest, Inc., K12 Inc., and CytRx Corporation; Long-Term Investors ... - PR Newswire (press release)
www.prnewswire.com - October 5 at 4:55 PM
Institutional Shareholder Services, Inc., Recommends CytRx ... - PR Newswire (press release)Institutional Shareholder Services, Inc., Recommends CytRx ... - PR Newswire (press release)
www.prnewswire.com - October 5 at 4:55 PM
Institutional Shareholder Services, Inc., Recommends CytRx Corporation Stockholders Vote "FOR" the Proposed Reverse Stock SplitInstitutional Shareholder Services, Inc., Recommends CytRx Corporation Stockholders Vote "FOR" the Proposed Reverse Stock Split
finance.yahoo.com - October 4 at 11:21 AM
Johnson Fistel, Announces Investigations of NantKwest, Inc., K12 Inc., and CytRx Corporation; Long-Term Investors Encouraged to Contact FirmJohnson Fistel, Announces Investigations of NantKwest, Inc., K12 Inc., and CytRx Corporation; Long-Term Investors Encouraged to Contact Firm
finance.yahoo.com - October 4 at 11:21 AM
BRIEF-CytRx Corp provides business update and highlights future plansBRIEF-CytRx Corp provides business update and highlights future plans
www.reuters.com - October 3 at 5:35 PM
CytRx Corporation Provides Business Update and Highlights Future Plans - PR Newswire (press release)CytRx Corporation Provides Business Update and Highlights Future Plans - PR Newswire (press release)
www.prnewswire.com - October 3 at 7:36 AM
CytRx Corporation Provides Business Update and Highlights Future PlansCytRx Corporation Provides Business Update and Highlights Future Plans
finance.yahoo.com - October 3 at 7:36 AM
BRIEF-CytRx corp says Glass Lewis & Co recommends CytRx stockholders vote "for" proposed reverse stock split​ - ReutersBRIEF-CytRx corp says Glass Lewis & Co recommends CytRx stockholders vote "for" proposed reverse stock split​ - Reuters
www.reuters.com - September 21 at 5:46 PM
Leading Independent Proxy Advisory Firm Glass Lewis & Co. Recommends CytRx Corp. Stockholders Vote "FOR" the ... - PR Newswire (press release)Leading Independent Proxy Advisory Firm Glass Lewis & Co. Recommends CytRx Corp. Stockholders Vote "FOR" the ... - PR Newswire (press release)
www.prnewswire.com - September 21 at 5:46 PM
Leading Independent Proxy Advisory Firm Glass Lewis & Co. Recommends CytRx Corp. Stockholders Vote "FOR" the Proposed Reverse Stock SplitLeading Independent Proxy Advisory Firm Glass Lewis & Co. Recommends CytRx Corp. Stockholders Vote "FOR" the Proposed Reverse Stock Split
finance.yahoo.com - September 21 at 9:48 AM
CytRx Corporation Announces Amendment to Definitive Proxy Statement for Upcoming Special Meeting - PR Newswire (press release)CytRx Corporation Announces Amendment to Definitive Proxy Statement for Upcoming Special Meeting - PR Newswire (press release)
www.prnewswire.com - September 14 at 11:33 PM

SEC Filings

CytRx (NASDAQ:CYTR) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

CytRx (NASDAQ:CYTR) Income Statement, Balance Sheet and Cash Flow Statement

Chart

CytRx (NASDAQ CYTR) Stock Chart for Monday, January, 22, 2018

Loading chart…

This page was last updated on 1/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.